One in Three High-Risk Outpatients Has CKD — and Most Go Undertreated
A Central European tertiary care study finds CKD in 32.5% of at-risk outpatients, with a major gap in renoprotective therapy use.
Summary
Chronic kidney disease is expected to become a top-five cause of death worldwide by 2040, yet most people with it don't know. Researchers in Prague screened 1,933 at-risk adults attending non-kidney specialty clinics (diabetes, liver, heart). About one in three (32.5%) had CKD, and roughly one in five screened patients without a prior diagnosis turned out to have it. Age, organ transplantation, hypertension, diabetes, heart failure or atrial fibrillation, and atherosclerosis all raised the odds. Even after adjusting for normal age-related kidney decline, prevalence stayed high at 27.8%. Kidney-protective drugs were underused: SGLT-2 inhibitors reached 42% of eligible patients, GLP-1 drugs 41.7%, and newer mineralocorticoid blockers just 6.7%. A model projected about 11 extra dialysis-free months per patient if treatment were optimized.
Detailed Summary
Chronic kidney disease (CKD) is projected to become the fifth leading cause of death globally by 2040, yet only about 20% of affected Europeans know they have it. Because kidney function declines with age and is tightly linked to diabetes, hypertension, and cardiovascular disease, CKD is a central healthspan problem. This study asked whether highly specialized internal medicine clinics, where patients are assumed to be well managed, are missing both CKD and the drugs that slow it.
The cross-sectional study ran from February to May 2025 at the Institute for Clinical and Experimental Medicine in Prague, across diabetology/endocrinology, hepatology/gastroenterology, and preventive medicine/cardiology clinics. Of 29,197 at-risk patients (older than 50 and/or with hypertension, diabetes, heart failure, atrial fibrillation, or atherosclerotic disease), screening was offered to 2,921 and 1,933 consented. Another 970 patients tested at their physician's discretion formed an enriched cohort of 2,903. CKD was defined by KDIGO criteria: eGFR below 60 or uACR above 3 mg/mmol.
CKD prevalence in the screened cohort was 32.5% (95% CrI 30.5 to 34.6). Reduced eGFR alone affected 21.7% and abnormal albuminuria 18.3%. Prevalence was 33.8% in men and 31.0% in women, rising from 13.6% of women and 17.1% of men aged 18-39 to 57.1% of women and 79.2% of men over 80. Screening uncovered 299 new cases, or one for every 5.2 previously undiagnosed patients screened. Using age-calibrated eGFR thresholds, prevalence fell only to 27.8%.
In the enriched cohort, adjusted odds of CKD rose with age (OR 3.81 per 25 years), non-renal transplantation (4.38), hypertension (2.61), type 1 diabetes (1.97), heart failure or atrial fibrillation (1.59), atherosclerotic disease (1.49), and type 2 diabetes (1.46). Type 1 diabetes was linked to lower odds of a new diagnosis (OR 0.55), likely because clinicians already watch these patients closely. Obesity had only a small unadjusted association with CKD, so it was left out of the main model and examined only in sensitivity analyses.
Treatment gaps were large. Among eligible patients, 78.6% of 593 received renin-angiotensin inhibitors, but only 42% (328/781) received SGLT-2 inhibitors, 41.7% (110/264) GLP-1 receptor agonists, and 6.7% (2/30) nonsteroidal mineralocorticoid antagonists. An exploratory model combining eGFR slopes from DAPA-CKD, FLOW, and FIDELIO-DKD with patient-specific survival estimated about 11.13 extra dialysis-free months per CKD patient with optimized therapy.
Several caveats apply. Eligibility could not be fully assessed and prescribing reasons were unknown, which may overstate treatment gaps. Single measurements may misclassify CKD, and the cross-sectional design limits causal inference. The dialysis-free projection assumes published trial effects transfer, act additively, and do not alter mortality, and its uncertainty was not fully propagated. It is a hypothesis-generating estimate, not a measured benefit.
Key Findings
- CKD prevalence was 32.5% (95% CrI 30.5 to 34.6) among 1,933 screened at-risk outpatients, and 27.8% after age-calibrated eGFR thresholds
- Screening found 299 new CKD cases: one new diagnosis per 5.2 previously undiagnosed patients screened; 20.3% already had known CKD
- CKD prevalence rose from 13.6% of women and 17.1% of men aged 18-39 to 57.1% of women and 79.2% of men over 80
- Strongest adjusted risk factors: non-renal organ transplant (OR 4.38), age (OR 3.81 per 25 years), hypertension (OR 2.61), type 1 diabetes (OR 1.97)
- SGLT-2 inhibitors reached only 42% of eligible patients (328/781) and GLP-1 receptor agonists 41.7% (110/264)
- Only 6.7% (2/30) of eligible patients received nonsteroidal mineralocorticoid receptor antagonists, versus 78.6% for RAAS inhibitors
- Exploratory modeling projected an average 11.13 additional dialysis-free months per CKD patient with optimized renoprotective therapy
Methodology
Cross-sectional study at one Prague tertiary center (Feb 24 to May 8, 2025) in diabetology/endocrinology, hepatology/gastroenterology, and preventive medicine/cardiology clinics. The Screening cohort had 1,933 consenting patients, and an Enriched cohort of 2,903 added 970 physician-tested patients. CKD was defined by KDIGO eGFR (2021 CKD-EPI) and uACR thresholds, plus an age-calibrated eGFR definition. Analyses used Bayesian logistic regression, with spline-based age modeling and screened/unscreened interaction terms. Medication use was cross-checked against the national electronic prescription registry. A scenario model combined trial-derived eGFR slopes (DAPA-CKD, FLOW, FIDELIO-DKD) with Cox-based survival to project dialysis-free time. The study was registered as NCT07153432.
Study Limitations
The authors note that missing data on prescribing decisions and incomplete checking of every eligibility criterion may overestimate treatment eligibility. Single laboratory measurements and the cross-sectional design may cause misclassification and prevent causal inference. The dialysis-free projection rests on extrapolated trial effects, assuming additivity, constant eGFR slopes, and no mortality effect, without comprehensive uncertainty propagation. The study was run at a single center, and no conflicts of interest were stated in the supplied text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
